{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:32:33Z","timestamp":1793377953256,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Government of Singapore Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"A*STAR Research Entities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022896","name":"Singapore Immunology Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymthe.2026.07.041","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:41:33Z","timestamp":1784590893000},"page":"5796-5817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas"],"prefix":"10.1016","volume":"34","author":[{"given":"Bei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5457-4331","authenticated-orcid":false,"given":"Yuanyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Yee Chin","family":"Yeap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve Zi Xian","family":"Ngoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mun Kuen","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Nazihah","family":"Mohd Salleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Izzah Nabilah","family":"Binte Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pavesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Adriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-2996","authenticated-orcid":false,"given":"Cheng-I","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.07.041_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2026.07.041_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2026.07.041_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137437","article-title":"Revisiting Epithelial Carcinogenesis","volume":"23","author":"M\u00e9ndez-L\u00f3pez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.07.041_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s43018-021-00181-0","article-title":"Emerging strategies for treating metastasis","volume":"2","author":"Esposito","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.07.041_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2026.07.041_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ymthe.2026.07.041_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13287-022-02819-x","article-title":"Hurdles to breakthrough in CAR T cell therapy of solid tumors","volume":"13","author":"Marofi","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ymthe.2026.07.041_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive\/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.07.041_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-024-01105-8","article-title":"Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial","volume":"14","author":"Wang","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2026.07.041_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40164-022-00352-4","article-title":"Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside","volume":"11","author":"Liu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib14","first-page":"138","article-title":"Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma","volume":"3","author":"Sears","year":"1984","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.ymthe.2026.07.041_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ijc.2910530508","article-title":"Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced","volume":"53","author":"Ragnhammar","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.07.041_bib16","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.1998.16.5.1788","article-title":"Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial","volume":"16","author":"Riethm\u00fcller","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/annonc\/mdp314","article-title":"An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer","volume":"21","author":"Schmidt","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/djs140","article-title":"Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma","volume":"104","author":"Moldenhauer","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2026.07.041_bib19","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE(R)) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.07.041_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1806009","article-title":"Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.07.041_bib21","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcgamma receptors","volume":"7","author":"Borlak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.07.041_bib22","article-title":"Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib23","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.07.041_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4161\/mabs.28614","article-title":"A novel human anti-interleukin-1beta neutralizing monoclonal antibody showing in vivo efficacy","volume":"6","author":"Goh","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.07.041_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2026.07.041_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.07.041_bib27","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.07.041_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00007691-199512000-00012","article-title":"Mechanisms of action and overview of OKT3","volume":"17","author":"Norman","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ymthe.2026.07.041_bib29","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.07.041_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41577-024-01011-x","article-title":"The OrganiX microfluidic system to recreate the complex tumour microenvironment","volume":"24","author":"Adriani","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123175","article-title":"In vitro integration of a functional vasculature to model endothelial regulation of chemotherapy and T-cell immunotherapy in liver cancer","volume":"320","author":"Vasudevan","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2026.07.041_bib32","article-title":"Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.07.041_bib33","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2026.07.041_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib35","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.07.041_bib36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/jcph.2346","article-title":"Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed\/Refractory Small Cell Lung Cancer (SCLC)","volume":"64","author":"Zhou","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib37","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2026.07.041_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020400","article-title":"Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance","volume":"12","author":"Mitani","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2026.07.041_bib39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10120-016-0627-z","article-title":"PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma","volume":"20","author":"Deguchi","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ymthe.2026.07.041_bib40","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/carcin\/bgq187","article-title":"EpCAM in carcinogenesis: the good, the bad or the ugly","volume":"31","author":"van der Gun","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ymthe.2026.07.041_bib41","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib42","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.07.041_bib43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.07.041_bib44","article-title":"Single domain Camelid antibody fragments for molecular imaging and therapy of cancer","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104342","article-title":"A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells","volume":"363","author":"Wang","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib48","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2407-6-165","article-title":"Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker","volume":"6","author":"Stoecklein","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2026.07.041_bib50","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2026.07.041_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/30.2.e9","article-title":"High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells","volume":"30","author":"Durocher","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.07.041_bib52","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.07.041_bib53","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed\/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:36:23Z","timestamp":1793374583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626006076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525001626006076"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.041","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}